THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced it has suspended its at-the-market offering of Company securities. On February 18, 2010 the Company announced it had retained Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE Amex: LTS), to execute the program as sales agent. At the time, due to SEC based regulatory limitations, Repros estimated that it would be limited to selling no more than approximately $7.8 million worth of its shares, due to the Company’s estimate of its public float on that date. As of this release date, the Company has raised approximately $6.8 million. Due to regulatory limitations Repros is suspending the offering. Currently the Company has 35,720,232 shares outstanding.
